Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01058174 (Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients), which is not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Secondary Analysis of a Systematic Review: Are Antifungal Noninferiority Trials at Risk of Eroding Effectiveness Because of Biocreep?Antimicrobial agents and chemotherapy · 2022Pooled it
- Pooled it
- Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Trial
- High Burden of Invasive Fungal Infection in Korean Pediatric Liver Transplant Recipients: A Single-Center Retrospective Cohort Study (2012-2023).Yonsei medical journal · 2026Article
- Early Tacrolimus C0/D Ratio and Subsequent Proven Invasive Fungal Disease After Liver Transplantation with Routine Early Echinocandin Prophylaxis.Infection and drug resistance · 2026Article
- Ultrastructural and Immunohistochemical Study on the Nephrotoxicity Following Intravitreal Administration of the Antifungal Agents Voriconazole and Micafungin in New Zealand White Rabbits.International journal of molecular sciences · 2025Article
- Limitations of antifungal prophylaxis in preventing invasiveAntimicrobial agents and chemotherapy · 2024Article
- Invasive Fungal Infections: The Early Killer after Liver Transplantation.Journal of fungi (Basel, Switzerland) · 2023Article
- Invasive Fungal Breakthrough Infections under Targeted Echinocandin Prophylaxis in High-Risk Liver Transplant Recipients.Journal of fungi (Basel, Switzerland) · 2023Article
- Incidence of Invasive Fungal Infections in Liver Transplant Recipients under Targeted Echinocandin Prophylaxis.Journal of clinical medicine · 2023Article
- Antifungal stewardship in solid organ transplantation.Transplant infectious disease : an official journal of the Transplantation Society · 2022Review
- Fungal infections following liver transplantation.World journal of hepatology · 2021Review
- Budget Impact of Microbial Cell-Free DNA Testing Using the KariusApplied health economics and health policy · 2021Article
- Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, andAntimicrobial agents and chemotherapy · 2021Article
- Invasive fungal infection before and after liver transplantation.World journal of gastroenterology · 2020Review
- Review
- Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.Antimicrobial agents and chemotherapy · 2018Article
- Detection of (1,3)-β-d-Glucan for the Diagnosis of Invasive Fungal Infection in Liver Transplant Recipients.International journal of molecular sciences · 2017Article
- Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results.BioMed research international · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 16 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive fungal infection (IFI) following liver transplant is associated with significant morbidity and mortality. Antifungal prophylaxis is rational for liver transplant patients at high IFI risk.
methodsIn this open-label, noninferiority study, patients were randomized 1:1 to receive intravenous micafungin 100 mg or center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant. The primary endpoint was clinical success (absence of a proven/probable IFI and no need for additional antifungals) at end of prophylaxis (EOP). Noninferiority (10% margin) of micafungin vs standard care was assessed in the per protocol and full analysis sets. Safety assessments included adverse events and liver and kidney function tests.
resultsThe full analysis set comprised 344 patients (172 micafungin; 172 standard care). Mean age was 51.2 years; 48.0% had a Model for End-Stage Liver Disease score ≥20. At EOP (mean treatment duration, 17 days), clinical success was 98.6% for micafungin and 99.3% for standard care (Δ standard care - micafungin [95% confidence interval], 0.7% [-2.7% to 4.4%]) in the per protocol set and 96.5% and 93.6%, respectively (-2.9% [-8.0% to 1.9%]), in the full analysis set. Incidences of drug-related adverse events for micafungin and standard care were 11.6% and 16.3%, leading to discontinuation in 6.4% and 11.6% of cases, respectively. At EOP, liver function tests were similar but creatinine clearance was higher in micafungin- vs standard care-treated patients.
conclusionsMicafungin was noninferior to standard care as antifungal prophylaxis in liver transplant patients at high risk for IFI. Adverse event profiles and liver function at EOP were similar, although kidney function was better with micafungin. CLINICAL TRIALS REGISTRATION: NCT01058174.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.